Long term follow up in all patients who received sar422459 in previous study tdu13583    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
301黄斑ジストロフィー1

301. 黄斑ジストロフィー [臨床試験数:41,薬物数:47(DrugBank:12),標的遺伝子数:12,標的パスウェイ数:66
Searched query = "Macular dystrophy", "Best disease", "Stargardt disease", "Cone dystrophy", "Cone rod dystrophy", "X-linked juvenile retinoschisis", "Central areolar choroidal dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 41 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01736592
(ClinicalTrials.gov)
December 14, 201226/11/2012Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular DegenerationAn Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular DegenerationStargardt's DiseaseDrug: Long term follow up in all patients who received SAR422459 in previous study TDU13583SanofiNULLActive, not recruiting6 YearsN/AAll27Phase 1;Phase 2United States;France